Editorial: HBV cure-the quest for biomarkers to predict off-treatment sustained response. Authors' reply

Affiliations

¹ Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
² Toronto Center for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Canada.

Editorial

Sylvia M Brakenhoff et al. Aliment Pharmacol Ther. 2021 Feb.

. 2021 Feb;53(4):555-556.

doi: 10.1111/apt.16233.

¹ Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
² Toronto Center for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Canada.

No abstract available

Comment on

Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss.
Brakenhoff SM, de Man RA, Boonstra A, van Campenhout MJH, de Knegt RJ, van Bömmel F, van der Eijk AA, Berg T, Hansen BE, Janssen HLA, Sonneveld MJ. Brakenhoff SM, et al. Aliment Pharmacol Ther. 2021 Jan;53(2):314-320. doi: 10.1111/apt.16172. Epub 2020 Nov 21. Aliment Pharmacol Ther. 2021. PMID: 33222190 Free PMC article.
Editorial: HBV cure-the quest for biomarkers to predict off-treatment sustained response.
Thibault V, Asselah T. Thibault V, et al. Aliment Pharmacol Ther. 2021 Feb;53(4):552-554. doi: 10.1111/apt.16214. Aliment Pharmacol Ther. 2021. PMID: 33616973 No abstract available.

1. Thibault V, Asselah T. Editorial: HBV cure – the quest for biomarkers to predict off‐treatment sustained response. Aliment Pharmacol Ther. 2021;53:552–554.
1. Brakenhoff SM, de Man RA, Boonstra A, et al. Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss. Aliment Pharmacol Ther. 2021;53:314–320.
1. Testoni B, Lebossé F, Scholtes C, et al. Serum hepatitis B core‐related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol. 2019;70:615‐625.
1. Sonneveld MJ. Core inhibitor therapy for chronic hepatitis B. Lancet Gastroenterol Hepatol. 2020;5:99‐100.
1. Reijnders JGP, Rijckborst V, Sonneveld MJ, et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol. 2011;54:449‐454.